Study of IMP321 as a Vaccine Adjuvant for Hepatitis B
Author Information
Author(s): Brignone Chrystelle, Grygar Caroline, Marcu Manon, Perrin Gaëlle, Triebel Frédéric
Primary Institution: Immutep S.A.
Hypothesis
Can IMP321 enhance T cell responses against HBsAg in healthy adults?
Conclusion
IMP321 as an adjuvant to HBsAg was well-tolerated and enhanced T cell response vaccine immunogenicity.
Supporting Evidence
- IMP321 was well tolerated with fewer adverse events compared to the Engerix-B group.
- HBsAg-specific antibody responses were higher in IMP321 recipients at 8 and 12 weeks.
- Increased numbers of responders to HBsAg were found in IMP321 recipients compared to the control group.
- CD4 Th1 antigen-specific T cells were induced in some individuals after just one injection of IMP321.
Takeaway
This study tested a new vaccine helper called IMP321 to see if it could make the hepatitis B vaccine work better, and it did!
Methodology
A single blind controlled phase I dose escalation study with 48 healthy volunteers receiving HBsAg with or without IMP321.
Potential Biases
Potential bias due to the single-blind design.
Limitations
The study had a small sample size and was limited to healthy adults aged 18-55.
Participant Demographics
Healthy adults aged 18-55, seronegative for HBV.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website